Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapiesAstellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Share XAstellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapieshttps://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/
FDA backs Astellas/Seattle Genetics bladder cancer drugThe FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the Share XFDA backs Astellas/Seattle Genetics bladder cancer drughttps://pharmaphorum.com/news/fda-backs-astellas-seattle-genetics-bladder-cancer-drug/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
Patient-partnered drug discovery: vision or reality?pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Share XPatient-partnered drug discovery: vision or reality?https://deep-dive.pharmaphorum.com/magazine/patient-engagement/astellas-patient-partnered-drug-discovery-vision-or-reality/
Astellas buys gene therapy company for $3bnAstellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of Share XAstellas buys gene therapy company for $3bnhttps://pharmaphorum.com/news/astellas-acquires-gene-therapy-company-for-3bn/
AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
